National Institute for Occupational Safety and Health; Changes to the Dose Reconstruction Target Organ Selection for Lymphoma Under the Energy Employees Occupational Illness Compensation Program Act of 2000, 7969-7970 [E6-2116]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 31 / Wednesday, February 15, 2006 / Notices
Dated: January 17, 2006.
Robert E. Polson,
Office of the Secretary, Paperwork Reduction
Act Reports Clearance Officer.
[FR Doc. E6–2121 Filed 2–14–06; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health; Changes to the
Dose Reconstruction Target Organ
Selection for Lymphoma Under the
Energy Employees Occupational
Illness Compensation Program Act of
2000
Authority: 42 CFR 82.32, 67 FR 22335–
22336.
Centers for Disease Control and
Prevention, HHS.
ACTION: Notice of a Change to a
Scientific Element Underlying Radiation
Dose Reconstructions under the Energy
Employees Occupational Illness
Compensation Program Act of 2000.
cprice-sewell on PROD1PC66 with NOTICES
AGENCY:
SUMMARY: The National Institute for
Occupational Safety and Health
(NIOSH) has changed the selection of
target organs used in dose
reconstructions NIOSH produces under
the Energy Employees Occupational
Illness Compensation Program Act of
2000 (EEOICPA) for energy employees
with lymphoma cancers. This change
responds to an evaluation by NIOSH of
current scientific data on lymphoma,
which revealed that the site of the
radiation injury can differ from the site
of the tumor or cancer origin
documented in the medical files of a
lymphoma cancer patient. The new
process for selecting dose reconstruction
target organs for energy employees with
lymphoma cancers includes selecting
the target organ that would have
received the highest radiation dose from
among relevant, possibly irradiated
organs, as determined through the dose
reconstruction process, when the
identity of the target organ is in
question. This change may result in the
Department of Labor calculating higher
probability of causation determinations
for select lymphoma cases among
previously decided and current
EEOICPA cancer claims.
FOR FURTHER INFORMATION CONTACT:
Larry Elliott, Director, Office of
Compensation Analysis and Support,
National Institute for Occupational
Safety and Health, 4676 Columbia
Parkway, Mailstop C–46, Cincinnati, OH
VerDate Aug<31>2005
13:17 Feb 14, 2006
Jkt 208001
45226, Telephone: (513) 533–6800 (This
is not a toll-free number).
SUPPLEMENTARY INFORMATION:
I. Summary of Public Comments
NIOSH accepted public comments on
this proposed change to NIOSH dose
reconstruction methods from January
19, 2006, through February 3, 2006.
NIOSH received 15 comments from
individuals.
Nine comments expressed support for
the new lymphoma procedure,
predicated on the condition that it
improves chances of compensation
being granted.
One comment objected to the different
treatment of ‘‘structural’’ lymphomas
(i.e., Hodgkin’s disease,
lymphosarcoma, reticulosarcoma, etc.)
versus non-Hodgkin’s and other
lymphomas. A NIOSH scientist
contacted the commenter and explained
the technical basis for these
distinctions, which in summary is that
tumor location is informative of the site
of radiation injury for such structural
lymphomas. Upon this explanation, the
commenter concurred with the
procedure as proposed by NIOSH.
Five comments concerned individual
claims for compensation rather than the
new lymphoma procedure.
II. Summary of Recommendations of
the ABRWH
The Advisory Board on Radiation and
Worker Health (ABRWH) discussed the
change and voted unanimously to
support it during a teleconference
meeting of the Board on January 9, 2006.
III. Summary of the Changes to the
Dose Reconstruction Target Organ
Selection for Lymphoma
NIOSH conducts radiation dose
reconstructions under EEOICPA in
compliance with the dose
reconstruction methods specified in
HHS regulations at 42 CFR part 82.
These regulations provide for NIOSH to
update its dose reconstruction methods
as necessary on the basis of improved
scientific understanding and specify a
process for deciding and implementing
such updates. 42 CFR 82.30–82.33.
Accordingly, NIOSH has updated its
method for reconstructing radiation
doses in cases involving certain
lymphoma cancers. Specifically, NIOSH
has changed its method for identifying
the target organ for which radiation
doses will be reconstructed in these
cases, for the reasons described below.
As required for certain updates in dose
reconstruction methods, NIOSH
presented the proposed change to the
ABRWH prior to implementation.
NIOSH has also considered all public
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
7969
comments concerning this change that
were received prior to the comment
deadline, as specified above.
NIOSH has re-examined the
appropriateness of the current method
of selecting dosimetry target organs for
lymphoma cases in light of the current
scientific knowledge on the diagnosis
and etiology of the various forms of
lymphoma.1 This re-examination has
revealed that for many non-Hodgkin’s
lymphomas, there were two problems
with NIOSH’s previous target organ
selection method. First, the site of
occurrence of the tumor is not
necessarily the site of the original
radiation injury. Second, the site listed
in the diagnosis may not actually be the
site of primary involvement. Rather, it is
common to list the site of the biopsy,
which may be selected on the basis of
medical considerations in terms of the
clinical symptoms and condition of the
patient and the ease of surgical access.
Both of these problems contributed to
the possibility that under the previous
method for select lymphoma cases,
NIOSH could not be certain its dose
reconstruction was based on the
biologically plausible organ with the
highest radiation dose.
As a result of this re-evaluation,
NIOSH has modified the selection of
target organs in select lymphoma cases
so that the organ that would have
received the highest radiation dose from
among relevant, possibly irradiated
organs, as determined through the dose
reconstruction process, is used in the
dose reconstruction. For the subset of
lymphomas where tumor location is
informative about the probable site of
original radiation injury (e.g. Hodgkin’s
disease, lymphosarcoma, etc.), the
information related to the site of
diagnosis will be considered in target
organ selection.
This change pertains only to the
selection of the appropriate target organ
as the site of radiation injury (i.e., for
calculation of effective radiation dose
during the dose reconstruction process).
It has no bearing on the selection of the
appropriate Interactive Radiological
Epidemiology Program (IREP) cancer
risk model for determining probability
1 Crowther, M. Consultant’s Report, Dose
Reconstruction Project. Prepared for the National
Institute for Occupational Safety and Health Office
of Compensation Analysis and Support. 2005;
Eckerman, K.F. Target Organs for Lymphatic and
Hematopoietic Cancers Comments/Suggestions.
Prepared for the National Institute for Occupational
Safety and Health Office of Compensation Analysis
and Support. 2005. Available online at: https://
www.cdc.gov/niosh/ocas/ocasdose.html (1.
Evaluation of Target Organ for Lymphomas; note,
this information can be found under the
‘‘Miscellaneous Items’’ section on this page).
E:\FR\FM\15FEN1.SGM
15FEN1
7970
Federal Register / Vol. 71, No. 31 / Wednesday, February 15, 2006 / Notices
of causation, nor does it impact the
cancer risk models themselves.
This change in NIOSH dose
reconstruction methods is likely to have
a substantial effect on certain EEOICPA
cancer cases involving lymphomas.
NIOSH will review all relevant
previously completed dose
reconstructions for cases that have not
been compensated to identify those for
which this new method is applicable,
and will re-complete these dose
reconstructions using this new method.
NIOSH will also apply this new method
in dose reconstructions for all currently
active lymphoma claims and any future
cases. Application of this new method
may result in the Department of Labor
calculating higher probability of
causation determinations for select
lymphoma cases among previously
decided and current EEOICPA cancer
claims.
The Director, National Institute for
Occupational Safety and Health
(NIOSH), has been delegated the
authority to sign Federal Register
notices for CDC that pertain to NIOSH
programmatic matters.
Dated: February 8, 2006.
John Howard,
Director, National Institute for Occupational
Safety and Health (NIOSH), Centers for
Disease Control and Prevention (CDC).
[FR Doc. E6–2116 Filed 2–14–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Place: Centers for Disease Control and
Prevention, 1600 Clifton Road, NE.,
Building 19, Room 254/255, Atlanta, GA
30333, Telephone Number 404–639–
3138.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section 552b(c)
(4) and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the review, discussion, and
evaluation of applications received in
response to: Developing Methodologies
to Determine the Prevalence of Autism
Spectrum Disorders in Early Childhood
and Young Adult Populations, RFA DD–
06–001.
For More Information Contact: M.
Chris Langub, Ph.D., Scientific Review
Administrator, Office of Public Health
Research, CDC, 1600 Clifton Road, NE.,
Mailstop D–72, Atlanta, GA 30333,
Telephone 404–639–4640.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: February 9, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–2138 Filed 2–14–06; 8:45 am]
BILLING CODE 4163–18–P
Disease, Disability, and Injury
Prevention and ControlSpecial
Emphasis Panels (SEP): Developing
Methodologies To Determine the
Prevalence of Autism Spectrum
Disorders in Early Childhood and
Young Adult Populations, RFA DD–06–
001
cprice-sewell on PROD1PC66 with NOTICES
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting:
Name: Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Developing
Methodologies to Determine the
Prevalence of Autism Spectrum
Disorders in Early Childhood and
Young Adult Populations, RFA DD–06–
001.
Time and Date: 8 a.m.–5 p.m., March
15, 2006 (Closed).
VerDate Aug<31>2005
13:17 Feb 14, 2006
Jkt 208001
Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request
Proposed Projects
Title: National Child Abuse and
Neglect Data System.
OMB No.: 6980–0229.
Description: The Administration on
Children, Youth and Families
established the National Child Abuse
and Neglect Data System (NCANDS) to
respond to the 1988 and 1992
amendments (Pub. L. 100–294 and Pub.
L. 102–295) to the Child Abuse
Prevention and Treatment Act (42
U.S.C. 5101 et seq.), as amended, which
called for the creation of a coordinated
national data collection and analysis
program, both universal and case-
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
specific in scope, to examine
standardized data on false, unfounded,
or unsubstantiated reports. In 1988,
ACYF embarked on a collaborative
effort with the States to develop a
voluntary national data collection and
analysis program to collect, compile,
and make available State child abuse
and neglect reporting information from
Child Protective Services agencies in the
50 States, the District of Columbia, and
the territories. The first request for
annual data was in July 1991. Data
collection has continued on an annual
basis. The Children’s Bureau is
currently preparing the 15th annual
report based on the NCANDS date.
In 1996, the Child Abuse Prevention
and Treatment Act was ameanded by
Public Law 104–235 to require that any
State receiving the Basic State Grant
work with the Secretary of the
Department of Health and Human
Services (HHS) to provide specific data
on child maltreatment to the extent
practicable. The legislation specified the
following data elements:
(1) The number of children who were
reported to the State during the year as
abused or neglected.
(2) Of the number of children described in
paragraph (1), the number with respect to
whome such reports were—
(A) Substantiated;
(B) Unsubstantiated; or
(C) Determined to be false.
(3) Of the number of children described in
paragraph (2)—
(A) The number who did not receive
services during the year under the State
program funded under this section or an
equivalent State program;
(B) The number who received services
during the year under the State program
funded under this section or an equivalent
State program; and
(C) The number who were removed from
their families during the year by disposition
of the case.
(4) The number of families who received
preventive services from the State during the
year.
(5) The number of deaths in the State
during the year resulting from child abuse or
neglect.
(6) Of the number of children described in
paragraph (5), the number of such children
who were in foster care.
(7) The number of Child Protective
Services workers responsible for the intake
and screening of reports filed in the previous
year.
(8) The agency response time with respect
to each such report with respect to initial
investigation of reports of child abuse or
neglect.
(9) The response time with respect to the
provision of services to families and children
where an allegation of abuse or neglect has
been made.
(10) The number of Child Protective
Services workers responsible for intake,
assessment, and investigation of child abuse
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 71, Number 31 (Wednesday, February 15, 2006)]
[Notices]
[Pages 7969-7970]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-2116]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health; Changes to
the Dose Reconstruction Target Organ Selection for Lymphoma Under the
Energy Employees Occupational Illness Compensation Program Act of 2000
Authority: 42 CFR 82.32, 67 FR 22335-22336.
AGENCY: Centers for Disease Control and Prevention, HHS.
ACTION: Notice of a Change to a Scientific Element Underlying Radiation
Dose Reconstructions under the Energy Employees Occupational Illness
Compensation Program Act of 2000.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) has changed the selection of target organs used in dose
reconstructions NIOSH produces under the Energy Employees Occupational
Illness Compensation Program Act of 2000 (EEOICPA) for energy employees
with lymphoma cancers. This change responds to an evaluation by NIOSH
of current scientific data on lymphoma, which revealed that the site of
the radiation injury can differ from the site of the tumor or cancer
origin documented in the medical files of a lymphoma cancer patient.
The new process for selecting dose reconstruction target organs for
energy employees with lymphoma cancers includes selecting the target
organ that would have received the highest radiation dose from among
relevant, possibly irradiated organs, as determined through the dose
reconstruction process, when the identity of the target organ is in
question. This change may result in the Department of Labor calculating
higher probability of causation determinations for select lymphoma
cases among previously decided and current EEOICPA cancer claims.
FOR FURTHER INFORMATION CONTACT: Larry Elliott, Director, Office of
Compensation Analysis and Support, National Institute for Occupational
Safety and Health, 4676 Columbia Parkway, Mailstop C-46, Cincinnati, OH
45226, Telephone: (513) 533-6800 (This is not a toll-free number).
SUPPLEMENTARY INFORMATION:
I. Summary of Public Comments
NIOSH accepted public comments on this proposed change to NIOSH
dose reconstruction methods from January 19, 2006, through February 3,
2006. NIOSH received 15 comments from individuals.
Nine comments expressed support for the new lymphoma procedure,
predicated on the condition that it improves chances of compensation
being granted.
One comment objected to the different treatment of ``structural''
lymphomas (i.e., Hodgkin's disease, lymphosarcoma, reticulosarcoma,
etc.) versus non-Hodgkin's and other lymphomas. A NIOSH scientist
contacted the commenter and explained the technical basis for these
distinctions, which in summary is that tumor location is informative of
the site of radiation injury for such structural lymphomas. Upon this
explanation, the commenter concurred with the procedure as proposed by
NIOSH.
Five comments concerned individual claims for compensation rather
than the new lymphoma procedure.
II. Summary of Recommendations of the ABRWH
The Advisory Board on Radiation and Worker Health (ABRWH) discussed
the change and voted unanimously to support it during a teleconference
meeting of the Board on January 9, 2006.
III. Summary of the Changes to the Dose Reconstruction Target Organ
Selection for Lymphoma
NIOSH conducts radiation dose reconstructions under EEOICPA in
compliance with the dose reconstruction methods specified in HHS
regulations at 42 CFR part 82. These regulations provide for NIOSH to
update its dose reconstruction methods as necessary on the basis of
improved scientific understanding and specify a process for deciding
and implementing such updates. 42 CFR 82.30-82.33. Accordingly, NIOSH
has updated its method for reconstructing radiation doses in cases
involving certain lymphoma cancers. Specifically, NIOSH has changed its
method for identifying the target organ for which radiation doses will
be reconstructed in these cases, for the reasons described below. As
required for certain updates in dose reconstruction methods, NIOSH
presented the proposed change to the ABRWH prior to implementation.
NIOSH has also considered all public comments concerning this change
that were received prior to the comment deadline, as specified above.
NIOSH has re-examined the appropriateness of the current method of
selecting dosimetry target organs for lymphoma cases in light of the
current scientific knowledge on the diagnosis and etiology of the
various forms of lymphoma.\1\ This re-examination has revealed that for
many non-Hodgkin's lymphomas, there were two problems with NIOSH's
previous target organ selection method. First, the site of occurrence
of the tumor is not necessarily the site of the original radiation
injury. Second, the site listed in the diagnosis may not actually be
the site of primary involvement. Rather, it is common to list the site
of the biopsy, which may be selected on the basis of medical
considerations in terms of the clinical symptoms and condition of the
patient and the ease of surgical access. Both of these problems
contributed to the possibility that under the previous method for
select lymphoma cases, NIOSH could not be certain its dose
reconstruction was based on the biologically plausible organ with the
highest radiation dose.
---------------------------------------------------------------------------
\1\ Crowther, M. Consultant's Report, Dose Reconstruction
Project. Prepared for the National Institute for Occupational Safety
and Health Office of Compensation Analysis and Support. 2005;
Eckerman, K.F. Target Organs for Lymphatic and Hematopoietic Cancers
Comments/Suggestions. Prepared for the National Institute for
Occupational Safety and Health Office of Compensation Analysis and
Support. 2005. Available online at: https://www.cdc.gov/niosh/ocas/
ocasdose.html (1. Evaluation of Target Organ for Lymphomas; note,
this information can be found under the ``Miscellaneous Items''
section on this page).
---------------------------------------------------------------------------
As a result of this re-evaluation, NIOSH has modified the selection
of target organs in select lymphoma cases so that the organ that would
have received the highest radiation dose from among relevant, possibly
irradiated organs, as determined through the dose reconstruction
process, is used in the dose reconstruction. For the subset of
lymphomas where tumor location is informative about the probable site
of original radiation injury (e.g. Hodgkin's disease, lymphosarcoma,
etc.), the information related to the site of diagnosis will be
considered in target organ selection.
This change pertains only to the selection of the appropriate
target organ as the site of radiation injury (i.e., for calculation of
effective radiation dose during the dose reconstruction process). It
has no bearing on the selection of the appropriate Interactive
Radiological Epidemiology Program (IREP) cancer risk model for
determining probability
[[Page 7970]]
of causation, nor does it impact the cancer risk models themselves.
This change in NIOSH dose reconstruction methods is likely to have
a substantial effect on certain EEOICPA cancer cases involving
lymphomas. NIOSH will review all relevant previously completed dose
reconstructions for cases that have not been compensated to identify
those for which this new method is applicable, and will re-complete
these dose reconstructions using this new method. NIOSH will also apply
this new method in dose reconstructions for all currently active
lymphoma claims and any future cases. Application of this new method
may result in the Department of Labor calculating higher probability of
causation determinations for select lymphoma cases among previously
decided and current EEOICPA cancer claims.
The Director, National Institute for Occupational Safety and Health
(NIOSH), has been delegated the authority to sign Federal Register
notices for CDC that pertain to NIOSH programmatic matters.
Dated: February 8, 2006.
John Howard,
Director, National Institute for Occupational Safety and Health
(NIOSH), Centers for Disease Control and Prevention (CDC).
[FR Doc. E6-2116 Filed 2-14-06; 8:45 am]
BILLING CODE 4163-18-P
